DL-AAA Retinal Leakage
Retinal vascular diseases such as wet age-related macular degeneration (wet AMD), diabetic macular edema, and retinal vein occlusion are driven in large part by vascular endothelial growth factor (VEGF). A key challenge in developing new anti-VEGF therapies is evaluating their duration of action in a model with chronic, stable vascular pathology.
Model Overview
DL-alpha-aminoadipic acid (DL-AAA) is a selective Müller cell toxin. When injected intravitreally in rabbits, it induces retinal neovascularization and chronic vascular leakage that stabilizes within 10–12 weeks and persists long-term. The leakage in this model is VEGF-dependent and is reversible with anti-VEGF treatment, returning to baseline after drug clearance. This makes it particularly well-suited for comparing the efficacy and duration of action of novel anti-angiogenic and sustained-release formulations.
Typical Endpoints
- Fluorescein angiography (FA): qualitative grading and quantification of retinal vascular leakage
- Fluorophotometry: quantification of fluorescein concentration in the vitreous
- Optical coherence tomography (OCT): structural assessment of the retina
- Color fundus photography: documentation of neovascular lesion morphology
- Histology and immunohistochemistry at study termination
Representative Data
Interested in this model?
We are happy to share more about study design options, endpoints, or timelines.
Contact us to discuss your study goals.
